TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Lytix Biopharma AS
Closing information (x1000 NOK)
| Closing information | 2019/12 | 2018/12 (consolidated) | 2017/12 (consolidated) |
| Turnover |
6,698
|
11,838
|
39,753 |
| Financial expenses |
338
|
511
|
21,157 |
| Earnings before taxes |
-32,415
|
-61,515
|
-69,429 |
| Total assets |
17,434
|
58,899
|
47,092 |
| Current assets |
17,434
|
58,899
|
47,086 |
| Current liabilities |
3,042
|
21,849
|
35,301 |
| Equity capital |
14,392
|
37,050
|
11,791 |
| - share capital |
2,289
|
2,249
|
1,234 |
| Employees (average) | 8 | 11 | |
| Shareholders | 0 | 0 | 0 |
Financial ratios
| Fiscal year | 2019/12 | 2018/12 (consolidated) | 2017/12 (consolidated) |
| Solvency |
82.6%
|
62.9%
|
25.0% |
| Turnover per employee | 837 | 3,614 | |
| Profit as a percentage of turnover |
-484.0%
|
-519.6%
|
-174.7% |
| Return on assets (ROA) |
-184.0%
|
-103.6%
|
-102.5% |
| Current ratio |
573.1%
|
269.6%
|
133.4% |
| Return on equity (ROE) |
-225.2%
|
-166.0%
|
-588.8% |
| Change turnover | |||
| Change turnover % |
-70%
|
219% | |
| Chg. No. of employees | |||
| Chg. No. of employees % | 0% |
Total value of public sale
| Fiscal year | 2019/12 | 2018/12 (consolidated) | 2017/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.